Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R.
Rolfes L, et al. Among authors: su c.
Mult Scler Relat Disord. 2022 Aug;64:103931. doi: 10.1016/j.msard.2022.103931. Epub 2022 May 29.
Mult Scler Relat Disord. 2022.
PMID: 35690010
Free article.